Laboratorios Farmaceuticos Rovi Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Laboratorios Farmaceuticos Rovi wird ein jährliches Gewinn- und Umsatzwachstum von 16.4% bzw. 9% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 16.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 23.2% betragen.
Wichtige Informationen
16.4%
Wachstumsrate der Gewinne
16.70%
EPS-Wachstumsrate
| Pharmaceuticals Gewinnwachstum | 20.6% |
| Wachstumsrate der Einnahmen | 9.0% |
| Zukünftige Eigenkapitalrendite | 23.24% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 01 Jun 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Analyseartikel • Nov 09
Here's What Analysts Are Forecasting For Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) After Its Third-Quarter Results
It's been a mediocre week for Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) shareholders, with the stock dropping...Analyseartikel • Nov 10
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
There's been a notable change in appetite for Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) shares in the week...Recent updates
Narrativ-Update • Jun 02
ROVI: Medium Term Contract Risks Will Still Support Future Returns
Analysts have trimmed the fair value estimate for Laboratorios Farmaceuticos Rovi from about €82.48 to €76.49 after recent downgrades flagged softer revenue growth assumptions, slightly lower profit margins and a modestly higher future P/E, with some noting medium term risks linked to Moderna exposure and declining vaccination volumes. Analyst Commentary Recent research has tilted more cautious on Laboratorios Farmaceuticos Rovi, with several downgrades pointing to a reassessment of growth, margins and risk tied to its partner exposure.Analyseartikel • Feb 09
Is Laboratorios Farmaceuticos Rovi (BME:ROVI) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Narrativ-Update • Feb 03
ROVI: Slightly Higher Fair Value And P/E Will Support Future Returns
Analysts have nudged their price target for Laboratorios Farmaceuticos Rovi slightly higher, with a modest upward revision in fair value tied to refreshed assumptions for revenue, profit margins and future P/E multiples. Valuation Changes Fair Value: Adjusted slightly higher from €81.97 to €82.48 per share, reflecting refreshed model assumptions.Narrativ-Update • Jan 20
ROVI: Stable Returns And Slightly Higher Multiple Will Support Future Earnings
Analysts have nudged up their fair value estimate for Laboratorios Farmaceuticos Rovi from €80.96 to €81.97, citing slightly higher revenue growth assumptions, a small adjustment in expected profit margins, and a modestly higher future P/E multiple as key drivers of the new target. Valuation Changes Fair Value Estimate was adjusted slightly from €80.96 to €81.97, reflecting a small uplift in the modelled valuation.Narrativ-Update • Jan 05
ROVI: Stable Returns And Margins Will Support Stronger Future Earnings
Analysts have kept their price target for Laboratorios Farmaceuticos Rovi unchanged, citing stable assumptions around a fair value of €80.96, a discount rate of 7.65%, revenue growth of 12.59%, a profit margin of 23.81% and a future P/E of 20.93 to support their view. Valuation Changes Fair Value: The fair value estimate remains unchanged at €80.96 per share, reflecting the same core valuation outcome as before.Narrativ-Update • Dec 15
ROVI: Stable Margins And Growth Outlook Will Support Stronger Future Earnings
Analysts have modestly adjusted their price targets for Laboratorios Farmaceuticos Rovi, now valuing the shares around €80.96. They reiterate expectations for solid double digit revenue growth, resilient profit margins, and a stable long term valuation multiple.Narrativ-Update • Dec 01
ROVI: Increasing Profit Margins Will Drive Stronger Earnings Outlook
Analysts have modestly increased their price target for Laboratorios Farmaceuticos Rovi to €80.96 per share. They cite improving profit margin forecasts as the primary driver of the change.Narrativ-Update • Nov 17
ROVI: Revenue Acceleration Projected To Drive Upside Despite Margin Pressure
Analysts have raised their price target for Laboratorios Farmaceuticos Rovi from €79.41 to €80.96. They cite improved revenue growth projections, despite slightly lower profit margins and a marginal increase in the discount rate.Analyseartikel • Nov 09
Here's What Analysts Are Forecasting For Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) After Its Third-Quarter Results
It's been a mediocre week for Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) shareholders, with the stock dropping...Analyseartikel • Nov 06
Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Jun 14
Laboratorios Farmaceuticos Rovi's (BME:ROVI) Dividend Will Be Reduced To €0.7574
Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) has announced that on 16th of July, it will be paying a dividend...Analyseartikel • May 27
Laboratorios Farmaceuticos Rovi's (BME:ROVI) Shareholders Will Receive A Smaller Dividend Than Last Year
Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) has announced that on 16th of July, it will be paying a dividend...Analyseartikel • Feb 09
We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Neues Narrativ • Dec 26
Okedi Expansion And Heparin Integration To Boost Revenue And Net Margins
Focus on Okedi and enoxaparin indicates potential revenue growth and improved profit margins from European development and heparin sales volume.Analyseartikel • Nov 10
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
There's been a notable change in appetite for Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) shares in the week...Analyseartikel • Oct 21
With Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) It Looks Like You'll Get What You Pay For
When close to half the companies in Spain have price-to-earnings ratios (or "P/E's") below 18x, you may consider...Analyseartikel • Aug 29
Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Jul 15
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Laboratorios Farmaceuticos Rovi fair value estimate is €146...Analyseartikel • Jun 17
We Take A Look At Why Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) CEO Has Earned Their Pay Packet
Key Insights Laboratorios Farmaceuticos Rovi will host its Annual General Meeting on 24th of June Salary of €743.0k is...Analyseartikel • May 08
Why We're Not Concerned About Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) Share Price
When close to half the companies in Spain have price-to-earnings ratios (or "P/E's") below 16x, you may consider...Analyseartikel • Apr 17
These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analyseartikel • Feb 14
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 26% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Laboratorios Farmaceuticos Rovi fair value estimate is €92.64...Analyseartikel • Dec 21
Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Nov 03
Is There An Opportunity With Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) 34% Undervaluation?
Key Insights The projected fair value for Laboratorios Farmaceuticos Rovi is €73.44 based on 2 Stage Free Cash Flow to...Analyseartikel • Aug 26
Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Jul 14
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 27% Below Their Intrinsic Value Estimate
Key Insights Laboratorios Farmaceuticos Rovi's estimated fair value is €52.88 based on 2 Stage Free Cash Flow to Equity...Analyseartikel • May 26
Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Analyseartikel • May 05
Do Laboratorios Farmaceuticos Rovi's (BME:ROVI) Earnings Warrant Your Attention?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analyseartikel • Apr 11
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 22% Below Their Intrinsic Value Estimate
Key Insights Laboratorios Farmaceuticos Rovi's estimated fair value is €51.68 based on 2 Stage Free Cash Flow to Equity...Analyseartikel • Feb 22
Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyseartikel • Dec 10
An Intrinsic Calculation For Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Suggests It's 48% Undervalued
In this article we are going to estimate the intrinsic value of Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) by...Analyseartikel • Nov 04
These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Safely
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Sep 15
Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Deserve A Spot On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analyseartikel • Aug 28
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Laboratorios...Analyseartikel • Jun 15
Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Feb 13
I Ran A Stock Scan For Earnings Growth And Laboratorios Farmaceuticos Rovi (BME:ROVI) Passed With Ease
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 987 | 217 | 165 | 223 | 8 |
| 12/31/2027 | 913 | 183 | 124 | 180 | 9 |
| 12/31/2026 | 774 | 133 | 95 | 167 | 8 |
| 3/31/2026 | 741 | 132 | 114 | 181 | N/A |
| 12/31/2025 | 743 | 140 | 119 | 187 | N/A |
| 9/30/2025 | 724 | 121 | 108 | 175 | N/A |
| 6/30/2025 | 749 | 132 | 72 | 137 | N/A |
| 3/31/2025 | 767 | 140 | 80 | 142 | N/A |
| 12/31/2024 | 764 | 137 | 76 | 138 | N/A |
| 9/30/2024 | 799 | 165 | 64 | 126 | N/A |
| 6/30/2024 | 778 | 148 | 35 | 90 | N/A |
| 3/31/2024 | 779 | 138 | 45 | 104 | N/A |
| 12/31/2023 | 830 | 170 | 58 | 113 | N/A |
| 9/30/2023 | 837 | 197 | 60 | 120 | N/A |
| 6/30/2023 | 818 | 186 | 61 | 121 | N/A |
| 3/31/2023 | 814 | 194 | 104 | 158 | N/A |
| 12/31/2022 | 818 | 200 | 186 | 238 | N/A |
| 9/30/2022 | 761 | 176 | 144 | 182 | N/A |
| 6/30/2022 | 739 | 183 | 192 | 232 | N/A |
| 3/31/2022 | 724 | 182 | 190 | 229 | N/A |
| 12/31/2021 | 649 | 153 | 109 | 149 | N/A |
| 9/30/2021 | 581 | 113 | 145 | 189 | N/A |
| 6/30/2021 | 519 | 82 | 105 | 149 | N/A |
| 3/31/2021 | 450 | 71 | 31 | 72 | N/A |
| 12/31/2020 | 420 | 61 | 7 | 47 | N/A |
| 9/30/2020 | 413 | 55 | -37 | -7 | N/A |
| 6/30/2020 | 395 | 53 | -52 | -27 | N/A |
| 3/31/2020 | 400 | 46 | -34 | -7 | N/A |
| 12/31/2019 | 381 | 39 | N/A | -9 | N/A |
| 9/30/2019 | 355 | 33 | N/A | 6 | N/A |
| 6/30/2019 | 334 | 27 | N/A | 12 | N/A |
| 3/31/2019 | 310 | 18 | N/A | 3 | N/A |
| 12/31/2018 | 303 | 18 | N/A | 9 | N/A |
| 9/30/2018 | 291 | 16 | N/A | 8 | N/A |
| 6/30/2018 | 283 | 9 | N/A | 16 | N/A |
| 3/31/2018 | 284 | 18 | N/A | 30 | N/A |
| 12/31/2017 | 276 | 17 | N/A | 18 | N/A |
| 9/30/2017 | 277 | 22 | N/A | 21 | N/A |
| 6/30/2017 | 275 | 24 | N/A | 25 | N/A |
| 3/31/2017 | 272 | 23 | N/A | 24 | N/A |
| 12/31/2016 | 265 | 26 | N/A | 46 | N/A |
| 9/30/2016 | 260 | 25 | N/A | 44 | N/A |
| 6/30/2016 | 254 | 24 | N/A | 38 | N/A |
| 3/31/2016 | 246 | 23 | N/A | 40 | N/A |
| 12/31/2015 | 246 | 20 | N/A | 29 | N/A |
| 9/30/2015 | 242 | 21 | N/A | 22 | N/A |
| 6/30/2015 | 243 | 23 | N/A | 27 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: ROVIDas prognostizierte Gewinnwachstum (16.4% pro Jahr) liegt über der Sparquote (2.7%).
Ertrag vs. Markt: ROVIDie Erträge des Unternehmens (16.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Spanish (11.5% pro Jahr).
Hohe Wachstumserträge: ROVIDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: ROVIDie Einnahmen des Unternehmens (9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Spanish (6.5% pro Jahr).
Hohe Wachstumseinnahmen: ROVIDie Einnahmen des Unternehmens (9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: ROVIDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (23.2%)
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/12 15:31 |
| Aktienkurs zum Tagesende | 2026/06/12 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Laboratorios Farmaceuticos Rovi, S.A. wird von 13 Analysten beobachtet. 9 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Luis Arredondo | Banco de Sabadell. S.A. |
| Jaime Escribano | Banco Santander |
| Patricia Cifuentes | Bestinver Sociedad De Valores, S.A |